PARSIPPANY, N.J., Dec. 17, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced that its molecular diagnostics subsidiary, Interpace Diagnostics, has launched its new next-generation sequencing (NGS) ThyGenX™ test to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules. Over 525,000 thyroid FNA's (fine needle aspirates) are performed annually and up to 30% of the results are indeterminate. ThyGenX is used to improve risk stratification to help minimize the need for unnecessary surgical procedures when standard cytopathology does not provide a clear diagnosis of thyroid cancer.
The test consists of a panel comprised of eight genes associated with papillary and follicular carcinoma, the two most common forms of thyroid malignancies. The ThyGenX panel design is based on the miRInform® test whose high predictive value has been validated in a recent prospective clinical study involving over 600 patients. Interpace Diagnostics acquired the miRInform test from Asuragen earlier this year, and has now enhanced it by upgrading to an NGS platform. NGS offers greater genomic insights and increases the panel content to over 100 known genetic alterations with strong correlation to malignant thyroid nodules.
"The launch of ThyGenX represents the next step in building Interpace Diagnostics' emerging endocrine cancer test franchise," said Nancy Lurker, CEO of PDI, Inc. "We are excited about the possibilities ahead as we continue to innovate and grow Interpace Diagnostics."
About PDI, Inc.
PDI is a leading healthcare commercialization company providing superior go-to-market strategy and execution to established and emerging healthcare companies through its three core business units. The company's Sales Services business unit (CSO) is a leading provider of outsourced pharmaceutical, medical device and diagnostics sales teams. PDI's Product Commercialization Services, including Interpace Diagnostics and the ThyGenX NGS Test, provides full product commercialization and is working to develop and commercialize molecular diagnostic tests leveraging the latest technology and personalized medicine for better patient diagnosis and management. Its Marketing Services division is a pioneer in insight-driven digital communication services and integrated multichannel message delivery. For more information about PDI, Inc. or Interpace Diagnostics, please visit http://www.pdi-inc.com and www.interpacediagnostics.com
Forward-Looking Statements
This press release contains forward-looking statements regarding future events and financial performance. These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond PDI's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause PDI's actual results to be materially different from those expressed or implied by any forward-looking statement. For example, with respect to statements regarding projections of future revenues, growth and profitability, estimated gross profit and anticipated internal rate of return on investments actual results may differ materially from those set forth in this release based on the loss, early termination or significant reduction of any of our existing service contracts, the failure to meet performance goals in PDI's incentive-based arrangements with customers, the inability to secure additional business or our inability to develop more predictable, higher margin business through in-licensing or other means. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including without limitation, PDI's previously filed Annual Report on Form 10-K for the year ended December 31, 2013 and current reports on Forms 10-Q and Forms 8-K. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Logo - http://photos.prnewswire.com/prnh/20140114/NY45872LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pdi-inc-subsidiary-interpace-diagnostics-announces-launch-of-thygenx-next-generation-sequencing-ngs-test-for-cancer-risk-assessment-of-thyroid-nodules-300011120.html
SOURCE PDI, Inc.
